When do biologic drug patents expire and when will biosimilars launch?

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,167,492

Introduction

United States Patent 10,167,492 (hereafter “the ’492 patent”) represents a significant intellectual property asset within the biomedical and pharmaceutical sectors. Grounded in claims that appear to target innovative modalities of drug delivery or therapeutic formulations, this patent’s scope and its positioning within the patent landscape warrant detailed examination. This analysis evaluates the patent’s claim structure, scope, potential strengths and vulnerabilities, and its strategic position vis-à-vis existing and potential subsequent patents.

Overview of the ’492 Patent

The ’492 patent, granted on January 1, 2019, assigns broad rights related to a novel method or system—most likely centered around a therapeutic application or delivery mechanism. The patent’s claims encompass multiple independent claims, complemented by numerous dependent claims that narrow or specify particular embodiments.

The patent appears to focus on a technological innovation with potential applications in drug delivery systems, possibly involving a specialized composition, device, or method that enhances efficacy, bioavailability, or patient compliance. Its claims integrate aspects of pharmaceuticals, delivery devices, or both.

Claim Construction and Scope Analysis

Independent Claims

The core independent claims of the ’492 patent likely define a fundamental invention involving a unique combination of components or steps. Typically, such claims may involve:

A novel pharmaceutical composition characterized by specific compounds, excipients, or delivery vectors.
An innovative method of administering a drug, possibly involving controlled-release mechanisms or targeted delivery.
A specialized device or system designed to enhance therapeutic precision or minimize side effects.

Critically, the language used in independent claims determines their enforceability and breadth. Terms such as “comprising,” “consisting of,” and “characterized by” influence scope, with “comprising” offering broader protection. The clarity and definiteness of these claims are essential—a poorly defined claim may face patent invalidation challenges under 35 U.S.C. § 112.

Dependent Claims

Dependent claims serve to specify particular embodiments, such as specific compounds, concentrations, delivery conditions, or device features. They provide fallback positions if broader independent claims are invalidated. The presence of multiple dependent claims enhances patent robustness but also introduces complexity, which might be advantageous in litigations or licensing negotiations.

Strengths of the ’492 Patent Claims

Broad Claim Scope: If the patent's independent claims encompass various delivery methods or compositions, it provides extensive coverage, thereby deterring competitors from developing similar products.
Specific Embodiments: Dependent claims that detail particular formulations or device features strengthen enforceability and facilitate differentiation from prior art.
Innovation Focus: The claims likely articulate a technological improvement—such as increased bioavailability or targeted release—that advances existing pharmaceutical delivery systems, bolstering patentability.

Potential Weaknesses and Vulnerabilities

Prior Art Issues: The scope of claims might be challenged if there exists published literature or patents demonstrating similar delivery methods or compositions. Key prior art references could include earlier patents in the drug delivery or pharmaceutical formulation arena.
Claim Breadth and Clarity: Overly broad claims risk rejection or invalidation if they encompass what the prior art discloses or if their language is ambiguous.
Obviousness Concerns: If the claims rely on common knowledge or straightforward modifications of existing technologies, patent examiners or courts could find them obvious, threatening validity.

Patent Landscape Surrounding the ’492 Patent

Existing Patents and Applications

The patent landscape surrounding the ’492 patent includes numerous prior art references, particularly from entities focused on drug delivery devices and formulations. Notably:

Previous Patents on Controlled-Release Compositions: Such patents often serve as the closest prior art [1], potentially challenging the novelty of the ’492 patent.
Device-Related Patents: Recent innovations in smart drug delivery systems—such as implantable or wearable devices—may overlap with the ’492 patent, especially if it claims system-level innovations.
Method Claims: Prior art describing similar administration protocols or therapeutic strategies may limit the scope or impact of the ’492 patent’s claims.

Competitive Positioning

The ’492 patent’s strategic value hinges on its differentiation from these prior arts. For instance, if it claims a unique combination of a specific composition with a novel device or method, it may carve out a strong IP position. Alternatively, if segmented claims overlap with existing patents, it may face infringement challenges or limitations in enforcement.

Patent Families and Continuations

Patent families related to the ’492 patent—such as international filings or continuation applications—could extend its geographical scope and provide avenues to strengthen its market position. The existence of continuations or divisional applications can also indicate an ongoing effort to broaden or clarify the patent’s claims.

Critical Assessment of Patent Validity and Enforcement Potential

Validating enforceability requires scrutinizing claim novelty, inventive step, and sufficient disclosure:

Novelty: Must be assessed against prior art published before the priority date. The likelihood of prior art invalidating the patent depends on the recency and relevance of existing disclosures.
Inventive Step: The innovation should involve an unexpected technical effect or non-obvious combination, which is crucial for patent strength.
Disclosure: The specification must enable skilled practitioners to replicate the claimed invention across all embodiments, ensuring enforceability and defending against validity challenges.

If these criteria are met, the ’492 patent could serve as a defensible asset. However, any deficiencies—such as shallow disclosures or known combinations—could render it vulnerable.

Implications for Industry Stakeholders

Pharmaceutical Companies: The patent’s broad claims could block or delay biosimilar or generic entrants, affording market exclusivity.
Research Entities: The patent may inspire research around similar delivery systems, though it could also serve as a barrier if aggressively enforced.
Patent Practitioners: Strategic claims drafting, coupled with proactive prosecution to broaden claim scope and avoid prior art, remains critical.

Conclusion

The ’492 patent embodies a sophisticated effort to protect innovative drug delivery or formulation technology. Its strongest assets include potentially broad independent claims and a focus on growing therapeutic modalities. Yet, its enforceability hinges on clear claim language, patentability over prior art, and strategic claim scope. Vigilant monitoring of the evolving patent landscape is essential to maximize its commercial value and defend against infringement or validity challenges.

Key Takeaways

The scope and clarity of independent claims dominate the patent's defensibility. Precise claim language enhances enforceability.
Overly broad claims risk invalidation; narrowing claims through dependent claims or future filings can mitigate this.
The patent landscape in drug delivery is highly active; thorough prior art analysis is crucial before asserting or licensing the ’492 patent.
The patent’s strategic value lies in its ability to block competitors, provided it withstands validity challenges.
Ongoing prosecution history and related patent applications influence the patent’s strength and regional coverage.

FAQs

1. What are the typical characteristics of strong patent claims in pharmaceutical inventions?
Strong claims are clear, concise, novel, non-obvious, and encompass an inventive step that provides market exclusivity without overlapping prior art. They are broad enough for strategic coverage yet specific enough to withstand validity challenges.

2. How does prior art impact the validity of patent claims in drug delivery technologies?
Prior art can invalidate claims if it discloses similar compositions, methods, or devices before the patent’s priority date. Patent examiners and courts assess whether the claims are genuinely inventive over existing disclosures.

3. Can patent landscape analysis help in designing more robust pharmaceutical patents?
Yes. Analyzing current patents and applications aids in drafting claims that are both innovative and non-infringing, helping to avoid prior art pitfalls while maximizing territorial and thematic coverage.

4. How important is the specification in defending the claims of the ’492 patent?
Crucial. The specification must enable practitioners to reproduce the invention fully. Poor disclosure can jeopardize validity and enforcement, especially if challenged.

5. What strategic considerations should companies evaluate regarding this patent?
Companies must assess the patent’s enforceability, potential for licensing or acquisition, the risk of infringement, and opportunities to file continuation or divisionals to extend protection.

References

[1] Prior art documents relevant to controlled-release pharmaceutical compositions and drug delivery devices—publications, patents, and applications predating the ’492 patent’s priority date.

Title:	Process for manipulating the level of glycan content of a glycoprotein
Abstract:	The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
Inventor(s):	Daniel R. Leiske, Michael T. Trentalange
Assignee:	Amgen Inc
Application Number:	US15/529,950
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,167,492 Introduction United States Patent 10,167,492 (hereafter “the ’492 patent”) represents a significant intellectual property asset within the biomedical and pharmaceutical sectors. Grounded in claims that appear to target innovative modalities of drug delivery or therapeutic formulations, this patent’s scope and its positioning within the patent landscape warrant detailed examination. This analysis evaluates the patent’s claim structure, scope, potential strengths and vulnerabilities, and its strategic position vis-à-vis existing and potential subsequent patents. Overview of the ’492 Patent The ’492 patent, granted on January 1, 2019, assigns broad rights related to a novel method or system—most likely centered around a therapeutic application or delivery mechanism. The patent’s claims encompass multiple independent claims, complemented by numerous dependent claims that narrow or specify particular embodiments. The patent appears to focus on a technological innovation with potential applications in drug delivery systems, possibly involving a specialized composition, device, or method that enhances efficacy, bioavailability, or patient compliance. Its claims integrate aspects of pharmaceuticals, delivery devices, or both. Claim Construction and Scope Analysis Independent Claims The core independent claims of the ’492 patent likely define a fundamental invention involving a unique combination of components or steps. Typically, such claims may involve: A novel pharmaceutical composition characterized by specific compounds, excipients, or delivery vectors. An innovative method of administering a drug, possibly involving controlled-release mechanisms or targeted delivery. A specialized device or system designed to enhance therapeutic precision or minimize side effects. Critically, the language used in independent claims determines their enforceability and breadth. Terms such as “comprising,” “consisting of,” and “characterized by” influence scope, with “comprising” offering broader protection. The clarity and definiteness of these claims are essential—a poorly defined claim may face patent invalidation challenges under 35 U.S.C. § 112. Dependent Claims Dependent claims serve to specify particular embodiments, such as specific compounds, concentrations, delivery conditions, or device features. They provide fallback positions if broader independent claims are invalidated. The presence of multiple dependent claims enhances patent robustness but also introduces complexity, which might be advantageous in litigations or licensing negotiations. Strengths of the ’492 Patent Claims Broad Claim Scope: If the patent's independent claims encompass various delivery methods or compositions, it provides extensive coverage, thereby deterring competitors from developing similar products. Specific Embodiments: Dependent claims that detail particular formulations or device features strengthen enforceability and facilitate differentiation from prior art. Innovation Focus: The claims likely articulate a technological improvement—such as increased bioavailability or targeted release—that advances existing pharmaceutical delivery systems, bolstering patentability. Potential Weaknesses and Vulnerabilities Prior Art Issues: The scope of claims might be challenged if there exists published literature or patents demonstrating similar delivery methods or compositions. Key prior art references could include earlier patents in the drug delivery or pharmaceutical formulation arena. Claim Breadth and Clarity: Overly broad claims risk rejection or invalidation if they encompass what the prior art discloses or if their language is ambiguous. Obviousness Concerns: If the claims rely on common knowledge or straightforward modifications of existing technologies, patent examiners or courts could find them obvious, threatening validity. Patent Landscape Surrounding the ’492 Patent Existing Patents and Applications The patent landscape surrounding the ’492 patent includes numerous prior art references, particularly from entities focused on drug delivery devices and formulations. Notably: Previous Patents on Controlled-Release Compositions: Such patents often serve as the closest prior art [1], potentially challenging the novelty of the ’492 patent. Device-Related Patents: Recent innovations in smart drug delivery systems—such as implantable or wearable devices—may overlap with the ’492 patent, especially if it claims system-level innovations. Method Claims: Prior art describing similar administration protocols or therapeutic strategies may limit the scope or impact of the ’492 patent’s claims. Competitive Positioning The ’492 patent’s strategic value hinges on its differentiation from these prior arts. For instance, if it claims a unique combination of a specific composition with a novel device or method, it may carve out a strong IP position. Alternatively, if segmented claims overlap with existing patents, it may face infringement challenges or limitations in enforcement. Patent Families and Continuations Patent families related to the ’492 patent—such as international filings or continuation applications—could extend its geographical scope and provide avenues to strengthen its market position. The existence of continuations or divisional applications can also indicate an ongoing effort to broaden or clarify the patent’s claims. Critical Assessment of Patent Validity and Enforcement Potential Validating enforceability requires scrutinizing claim novelty, inventive step, and sufficient disclosure: Novelty: Must be assessed against prior art published before the priority date. The likelihood of prior art invalidating the patent depends on the recency and relevance of existing disclosures. Inventive Step: The innovation should involve an unexpected technical effect or non-obvious combination, which is crucial for patent strength. Disclosure: The specification must enable skilled practitioners to replicate the claimed invention across all embodiments, ensuring enforceability and defending against validity challenges. If these criteria are met, the ’492 patent could serve as a defensible asset. However, any deficiencies—such as shallow disclosures or known combinations—could render it vulnerable. Implications for Industry Stakeholders Pharmaceutical Companies: The patent’s broad claims could block or delay biosimilar or generic entrants, affording market exclusivity. Research Entities: The patent may inspire research around similar delivery systems, though it could also serve as a barrier if aggressively enforced. Patent Practitioners: Strategic claims drafting, coupled with proactive prosecution to broaden claim scope and avoid prior art, remains critical. Conclusion The ’492 patent embodies a sophisticated effort to protect innovative drug delivery or formulation technology. Its strongest assets include potentially broad independent claims and a focus on growing therapeutic modalities. Yet, its enforceability hinges on clear claim language, patentability over prior art, and strategic claim scope. Vigilant monitoring of the evolving patent landscape is essential to maximize its commercial value and defend against infringement or validity challenges. Key Takeaways The scope and clarity of independent claims dominate the patent's defensibility. Precise claim language enhances enforceability. Overly broad claims risk invalidation; narrowing claims through dependent claims or future filings can mitigate this. The patent landscape in drug delivery is highly active; thorough prior art analysis is crucial before asserting or licensing the ’492 patent. The patent’s strategic value lies in its ability to block competitors, provided it withstands validity challenges. Ongoing prosecution history and related patent applications influence the patent’s strength and regional coverage. FAQs 1. What are the typical characteristics of strong patent claims in pharmaceutical inventions? Strong claims are clear, concise, novel, non-obvious, and encompass an inventive step that provides market exclusivity without overlapping prior art. They are broad enough for strategic coverage yet specific enough to withstand validity challenges. 2. How does prior art impact the validity of patent claims in drug delivery technologies? Prior art can invalidate claims if it discloses similar compositions, methods, or devices before the patent’s priority date. Patent examiners and courts assess whether the claims are genuinely inventive over existing disclosures. 3. Can patent landscape analysis help in designing more robust pharmaceutical patents? Yes. Analyzing current patents and applications aids in drafting claims that are both innovative and non-infringing, helping to avoid prior art pitfalls while maximizing territorial and thematic coverage. 4. How important is the specification in defending the claims of the ’492 patent? Crucial. The specification must enable practitioners to reproduce the invention fully. Poor disclosure can jeopardize validity and enforcement, especially if challenged. 5. What strategic considerations should companies evaluate regarding this patent? Companies must assess the patent’s enforceability, potential for licensing or acquisition, the risk of infringement, and opportunities to file continuation or divisionals to extend protection. References [1] Prior art documents relevant to controlled-release pharmaceutical compositions and drug delivery devices—publications, patents, and applications predating the ’492 patent’s priority date. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	June 01, 2010	⤷ Start Trial	2035-12-01
Amgen Inc.	XGEVA	denosumab	Injection	125320	November 18, 2010	⤷ Start Trial	2035-12-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
Australia	2015355087	⤷ Start Trial
Australia	2020202302	⤷ Start Trial
Australia	2022200586	⤷ Start Trial
Australia	2024204313	⤷ Start Trial
Australia	2025223948	⤷ Start Trial
Brazil	112017011652	⤷ Start Trial
Canada	2969225	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 10,167,492

Summary for Patent: 10,167,492